A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes

Assessing achievement and maintenance of glycemic control by patients initiating basal insulin

“…However, evidence is limited regarding the effectiveness of basal insulin in a real-world setting [5][6][7] .…”

“…In an analysis of the administrative health care claims of patients initiating either insulin detemir or insulin glargine in the US, researchers found that 26% of these patients achieved an HbA1c level 57.0% after six months 7 . Poor glycemic control outcomes have been linked to low adherence to insulin treatment, inadequate titration of insulin dosage, therapeutic inertia, and the progressive loss of beta cell function 8 .…”

“…Unchecked hyperglycemia has been linked to increased morbidity in large epidemiologic studies [2][3][4] . The American Association of Clinical Endocrinologists (AACE), American College of Endocrinology (ACE), American Diabetes Association (ADA), and the European Association for the Study of Diabetes (EASD) all identified the successful management of hyperglycemia among patients with diabetes as a top priority [5][6][7] . Many patients achieve glycemic goals with lifestyle modifications and oral antidiabetic drugs, but some patients require the inclusion of insulin in their treatment regimen.…”

Long-Acting Insulin Analogs: A Review of “Real-World” Effectiveness in Patients with Type 2 Diabetes

“…insulin detemir [24,29,36,40,[44][45][46][47][48][49][50]. In many routine clinical practice studies, therefore, a considerable proportion of patients remain above recommended glycemic targets despite transition to insulin.…”

Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis

“…This often results in low treatment persistence, which has been defined as the proportion of patients who remained on treatment for a specific time or the duration of time from initiation to discontinuation of therapy [5,6]. Few studies have examined the persistence of type 2 diabetes patients on basal insulins in a real-world setting and previous results have been somewhat controversial [7,8]. In Germany, there is a lack of real-world evidence studies on the basal insulin treatment persistence and related factors in type 2 diabetes patients in primary care.…”